Sign in Subscribe
Cancer

Sunshine Biopharma Receives Approval for Domperidone from Health Canada

Strategic Insights

— 1 min read

Sunshine Biopharma Inc.'s wholly owned subsidiary, Nora Pharma Inc., has achieved a significant milestone with the approval from Health Canada for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting. This approval marks a strategic expansion into the generic pharmaceuticals market for Sunshine Biopharma, further solidifying its presence in the industry. Domperidone's efficacy in treating chemotherapy-induced nausea and vomiting makes it a crucial addition to the company's growing generics portfolio.

Key Takeaways:

  • The approval of Domperidone by Health Canada is a significant milestone for Sunshine Biopharma's strategic expansion into the generic pharmaceuticals market.
  • Domperidone is a widely prescribed medication for gastrointestinal disorders, recognized for its efficacy and safety profile.
  • The North American Domperidone industry is projected to reach $781 million USD by 2033, with a CAGR of 4.89%.
  • The approximate market share for each of the three North American countries in 2025 is: United States (73.7%), Canada (17.0%), Mexico (9.30%).
  • Sunshine Biopharma currently has 76 generic prescription drugs on the market in Canada and more than 12 additional drugs scheduled to be launched in 2026.
  • The company is conducting a proprietary drug development program consisting of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.

Statistics:

  • Global sales of Domperidone are projected to reach $1.36 billion USD by the end of 2025.
  • The North American Domperidone industry grew from $440 million USD in 2021 to $533 million USD in 2025.
  • The approximate costs of Domperidone in 2025 include:

+ India: $15 per unit (1,000 units).

+ Brazil: $20 per unit (1,000 units).

+ Middle East: $30 per unit (1,000 units).

Sources:

  • Sunshine Biopharma Inc. press release, October 28, 2025, ACCESS Newswire.
  • Cognitive Market Research, global sales projections for Domperidone by 2025.

Read more